Nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator that activates the cellular defense system against oxidative stress, which improves oxidative stress-related disease conditions. Under unstressed conditions, NRF2 is constitutively ubiquitinated via its interaction with Kelch-like ECH-associated protein 1 (KEAP1) and degraded by the proteasomal pathway, thereby limiting the NRF2-induced antioxidative effects. Thus, the NRF2/KEAP1 axis is essential for protection against diseases in which oxidative stress and inflammation are the underlying pathological features. These include metabolic and inflammatory/autoimmune disorders, neurological conditions, and diseases of the eye, lung, liver, kidney, gastrointestinal tract, and cardiovascular system.

We identified a new small molecule that can specifically inhibit the interaction of NRF2 and KEAP1, which may be an effective and safe strategy. SCO-116, identified by SCOHIA researchers, is a novel activator of NRF2 that selectively inhibits its interaction with KEAP1. SCO-116 is available as an oral or injectable form and effectively activates NRF2 pathways in target organs upon its administration with a good safety profile.

Preclinical evaluations required for a first-in-human study are ongoing.

SCOHIA is actively seeking partnerships worldwide for the development and commercialization of SCO-116 (Contact here for partnering).

Indication

  • Diabetic kidney disease (DKD)
  • Chronic kidney disease (CKD)
  • Eye diseases
  • Lung diseases
  • Nonalcoholic steatohepatitis (NASH)
  • Antioxidant effect
SCO-116
Cytoplasm
KEAP1
NRF2

KEAP1-NRF2
interaction
inhibition

Nucleus

NRF2 activation

NASH

肝臓

Anti-fibrosis
Anti-fatty liver

CKD/DKD

腎臓

GFR increase
Anti-fibrosis

Other oxidative stress
related diseases